|
|
|
|
InfergenFinanzen.net, NYSE:VRX) todayannounced that it has completed its acquisition of the United Statesand Canadian rights to the hepatitis C drug Infergen(R) (interferonalfacon-1 ... Valeant Pharmaceuticals Completes Acquisition of Hep-C Drug ... Jan 3, 2006 Business Wire (press release), NYSE:VRX) today announced that it has completed its acquisition of the United States and Canadian rights to the hepatitis C drug Infergen(R) (interferon alfacon ... InterMune Completes Divestiture of Infergen(R) for up to $135.5 ... Jan 3, 2006 PR Newswire (press release), ...(Nasdaq: ITMN) announced today the completion of the sale of its United States and Canadian rights to Infergen(R) (interferon alfacon-1), approved for the ... Valeant buys InterMune hepatitis C drug Jan 3, 2006 San Francisco Business Times, Valeant Pharmaceuticals International said Tuesday it closed its purchase of the United States and Canadian rights to hepatitis C drug Infergen from InterMune ... (PRN) - SPADE Defense Index Outperforms S&P 500 for Sixth ... Jan 3, 2006 Bolsamania.com, Research Segment Restructuring ... [+. PRN) - InterMune Completes Divestiture of Infergen(R) for up to $135.5 Million in Cash ... [+. Zacks.com announces that Richard Moroney highlights the following ... Dec 15, 2005 Business Wire (press release), They manufacture and market four human therapeutic products, EPOGEN(R) (Epoetin alfa), NEUPOGEN(R) (Filgrastim), INFERGEN(R) (Interferon alfacon-1) and STEMGEN ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |